• DOI:10.1182/blood-2013-02-484832
Corpus ID: 20843763

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

@article{Komrokji2015ResultsOA,
  title={Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.},
  author={R. Komrokji and J. Seymour and A. Roberts and M. Wadleigh and L. To and R. Scherber and E. Turba and A. Dorr and Joy Zhu and Lixia Wang and T. Granston and M. Campbell and R. Mesa},
  journal={Blood},
  year={2015},
  volume={125 17},
  pages={
          2649-55
        }
}

• R. Komrokji, J. Seymour, +10 authors R. Mesa
• Published 2015
• Medicine
• Blood

Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable safety profile with promising efficacy in phase 1 studies in patients with primary and secondary myelofibrosis (MF). This multicenter phase 2 study further characterized the safety and efficacy of pacritinib in the treatment of patients with MF. Eligible patients had clinical splenomegaly poorly controlled with standard therapies or were… Expand

View on PubMed

ashpublications.org

Save to Library

Create Alert

Cite

Launch Research Feed